Insomnia Market: Industry Analysis and forecast (2019 to 2027): By Prescription Sleep Aids, Over-the-Counter Sleep Aids, Non-pharmacological Treatment, and Region

Insomnia Market: Industry Analysis and forecast (2019 to 2027): By Prescription Sleep Aids, Over-the-Counter Sleep Aids, Non-pharmacological Treatment, and Region

Market Scenario

Insomnia Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2027, at CAGR of XX% during forecast period of 2019 to 2027. Insomnia Market As per the scientific proofs reported by American Psychiatric Association (APA) about one third of the adults suffer with insomnia during their generation. Insomnia is a sleep disorder where in the person faces difficultly to remain asleep or sleep. The symptoms of insomnia are depression, daytime sleepiness, low stamina and irritability. It is a highly prevalent disorder that affect millions of individuals, globally. Insomnia-related conditions are caused because of disturbance in chronic pain, circadian rhythm, hyperthyroidism, psychological stress, menopause, and other medical conditions. Furthermore, excessive use of drugs such as alcohol, caeine, and nicotine could lead to insomnia. This syndrome can be diagnosed in sleep laboratories using various diagnostic devices. Depending on the period of the disorder, insomnia disease segmented into three types, chronic, acute, and transient insomnia. In transient insomnia, the symptoms persevere from a few days to few weeks. Acute insomnia perseveres for several weeks. Chronic insomnia last for months to a few years.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Insomnia Market Drivers and Restrains An increasing in the launch of new sleep-inducing drugs, devices, and treatments is anticipated to drive the insomnia market growth. For example, the Insomnia Clinic in Bloomsbury has developed a new treatment for insomnia. The clinical trials for the Insomnia showed positive results where 80% of the patients displayed remarkable improvements. Likewise, Eisai Inc has developed a drug called lemborexant (dual orexin receptor antagonist), adual orexin receptor antagonist that anticipated to be effective for the treatment of the older population with insomnia. Positive results and low price of devices are predictable to be the major factors promoting demand for devices. Insomnia therapeutic devices have started gaining traction in developed countries such as Norway, Switzerland, Australia and Ireland. Medical devices have benefits like the fast onset of sleep and longer sleep maintenance among patients who have negative results through drugs. New technical devices like Alpha-Stim AID, Ebb Insomnia Therapy, and Fisher Wallace Stimulator have already received approvals from FDA. The Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is anticipated to be launched in the early phase during forecast period. Manufacturers in the Insomnia are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. Insomnia Market Segmentation Analysis The global insomnia market is segmented based on treatment type and regionally. In terms of therapy type, it is split into non-pharmacological and pharmacological therapy. Non-pharmacological therapy is further categorized into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. In pharmacological therapy is further divided into over-the-counter sleep aids and prescription sleep aids. Furthermore, Prescription Sleep Aids market subdivided into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor antagonists, and other prescription sleep aids. Whereas, Over-the-Counter Sleep Aids market segmented into antihistamines, melatonin, valerian roots and other herbal & dietary supplements. Based on region, it is studied across Asia Pacific, North America, Europe, Latin America and Middle East Africa. Insomnia Market Regional Analysis On the basis of region Insomnia Market divided into five region such as Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among all the regions, North America had hold the largest market share in 2018 and is projected to lead the market during the forecast period. Asia Pacific without Japan is also expected to be a dominant region for the insomnia market’s growth. The reason for this is attributable to the increasing shift-related work in this region causing numerous sleep disorders. The rising urban population in this region has also driven the market’s expansion. Indonesia, India, and China are expected to be leading regions for the market’s growth in this region. According to Centers for Disease Control and Prevention (CDCP), approximately XX million adults in the United State suffered from insomnia disease. This is a result of the unhealthy lifestyle and rising stress levels among the population. Apart from the U.S., Canada has also highly contributed to the insomnia market’s growth in this region. The objective of the report is to present comprehensive analysis of Insomnia Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Insomnia Market dynamics, structure by analyzing the market segments, and project the Insomnia Market size. Clear representation of competitive analysis of key players by Insomnia Type, price, financial position, product portfolio, growth strategies, and regional presence in the Insomnia Market make the report investor’s guide.

Scope of the Insomnia Market

Insomnia Market, by Prescription Sleep Aids

• Non-benzodiazepines • Benzodiazepines • Orexin Antagonists • Melatonin Receptor Antagonists • Other Prescription Sleep Aids

Insomnia Market, by Over-the-Counter Sleep Aids

• Antihistamines • Melatonin • Valerian Roots • Other Herbal & Dietary Supplements

Insomnia Market, Non-pharmacological Treatment

• Cognitive Behavioral Therapy for Insomnia (CBTI) • Hypnotherapy • Other Alternative Therapies

Insomnia Market, by Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Insomnia Market, Major Players

• Astellas • Biocodex S A • Consumer Healthcare Inc. • Dainippon Sumitomo • ECR Pharmaceuticals • Eisai Co. • Flynn Pharma • Johnson and Johnson • Meda Consumer Healthcare Inc. • Merck and Co. Inc. • Neurim • Pernix Therapeutics • Pfizer Inc • Purdue Pharma L.P. • Sanofi Pasteur • SkyePharma • Takeda Pharmaceutical Company

Table of Contents

Insomnia Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Insomnia Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Insomnia Market Analysis and Forecast 6.1. Global Insomnia Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Insomnia Market Analysis and Forecast, by Over-the-Counter Sleep Aids 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 7.4. Global Insomnia Market Size (US$ Bn) Forecast, by Over-the-Counter Sleep Aids 7.5. Global Insomnia Market Analysis, by Over-the-Counter Sleep Aids 7.6. Global Insomnia Market Attractiveness Analysis, by Over-the-Counter Sleep Aids 8. Global Insomnia Market Analysis and Forecast, Non-pharmacological Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Insomnia Market Value Share Analysis, Non-pharmacological Treatment 8.4. Global Insomnia Market Size (US$ Bn) Forecast, Non-pharmacological Treatment 8.5. Global Insomnia Market Analysis, Non-pharmacological Treatment 8.6. Global Insomnia Market Attractiveness Analysis, Non-pharmacological Treatment 9. Global Insomnia Market Analysis and Forecast, by Prescription Sleep Aids 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Insomnia Market Value Share Analysis, by Prescription Sleep Aids 9.4. Global Insomnia Market Size (US$ Bn) Forecast, by Prescription Sleep Aids 9.5. Global Insomnia Market Analysis, by Prescription Sleep Aids 9.6. Global Insomnia Market Attractiveness Analysis, by Prescription Sleep Aids 10. Global Insomnia Market Analysis, by Region 10.1. Global Insomnia Market Value Share Analysis, by Region 10.2. Global Insomnia Market Size (US$ Bn) Forecast, by Region 10.3. Global Insomnia Market Attractiveness Analysis, by Region 11. North America Insomnia Market Analysis 11.1. Key Findings 11.2. North America Insomnia Market Overview 11.3. North America Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 11.4. North America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.4.1.1. Antihistamines 11.4.1.2. Melatonin 11.4.1.3. Valerian Roots 11.4.1.4. Other Herbal & Dietary Supplements 11.5. North America Insomnia Market Value Share Analysis, Non-pharmacological Treatment 11.6. North America Insomnia Market Forecast, Non-pharmacological Treatment 11.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.6.2. Hypnotherapy 11.6.3. Other Alternative Therapies 11.7. North America Insomnia Market Value Share Analysis, by Prescription Sleep Aids 11.8. North America Insomnia Market Forecast, by Prescription Sleep Aids 11.8.1. Non-benzodiazepines 11.8.2. Benzodiazepines 11.8.3. Orexin Antagonists 11.8.4. Melatonin Receptor Antagonists 11.8.5. Other Prescription Sleep Aids 11.9. North America Insomnia Market Value Share Analysis, by Country 11.10. North America Insomnia Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Insomnia Market Analysis, by Country 11.12. U.S. Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.12.1.1. Antihistamines 11.12.1.2. Melatonin 11.12.1.3. Valerian Roots 11.12.1.4. Other Herbal & Dietary Supplements 11.13. U.S. Insomnia Market Forecast, Non-pharmacological Treatment 11.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.13.2. Hypnotherapy 11.13.3. Other Alternative Therapies 11.14. U.S. Insomnia Market Forecast, by Prescription Sleep Aids 11.14.1.1. Non-benzodiazepines 11.14.1.2. Benzodiazepines 11.14.1.3. Orexin Antagonists 11.14.1.4. Melatonin Receptor Antagonists 11.14.1.5. Other Prescription Sleep Aids 11.15. Canada Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.15.1.1. Antihistamines 11.15.1.2. Melatonin 11.15.1.3. Valerian Roots 11.15.1.4. Other Herbal & Dietary Supplements 11.16. Steel Canada Insomnia Market Forecast, Non-pharmacological Treatment 11.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.16.2. Hypnotherapy 11.16.3. Others2 11.17. Canada Insomnia Market Forecast, by Prescription Sleep Aids 11.17.1. Non-benzodiazepines 11.17.2. Benzodiazepines 11.17.3. Orexin Antagonists 11.17.4. Melatonin Receptor Antagonists 11.17.5. Other Prescription Sleep Aids 11.18. North America Insomnia Market Attractiveness Analysis 11.18.1. By Over-the-Counter Sleep Aids 11.18.2. Non-pharmacological Treatment 11.18.3. By Prescription Sleep Aids 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Insomnia Market Analysis 12.1. Key Findings 12.2. Europe Insomnia Market Overview 12.3. Europe Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 12.4. Europe Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.4.1.1. Antihistamines 12.4.1.2. Melatonin 12.4.1.3. Valerian Roots 12.4.1.4. Other Herbal & Dietary Supplements 12.5. Europe Insomnia Market Value Share Analysis, Non-pharmacological Treatment 12.6. Europe Insomnia Market Forecast, Non-pharmacological Treatment 12.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.6.2. Hypnotherapy 12.6.3. Other Alternative Therapies 12.7. Europe Insomnia Market Value Share Analysis, by Prescription Sleep Aids 12.8. Europe Insomnia Market Forecast, by Prescription Sleep Aids 12.8.1. Non-benzodiazepines 12.8.2. Benzodiazepines 12.8.3. Orexin Antagonists 12.8.4. Melatonin Receptor Antagonists 12.8.5. Other Prescription Sleep Aids 12.9. Europe Insomnia Market Value Share Analysis, by Country 12.10. Europe Insomnia Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Insomnia Market Analysis, by Country 12.12. Germany Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.12.1.1. Antihistamines 12.12.1.2. Melatonin 12.12.1.3. Valerian Roots 12.12.1.4. Other Herbal & Dietary Supplements 12.13. Germany Insomnia Market Forecast, Non-pharmacological Treatment 12.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.13.2. Hypnotherapy 12.13.3. Other Alternative Therapies 12.14. Germany Insomnia Market Forecast, by Prescription Sleep Aids 12.14.1. Non-benzodiazepines 12.14.2. Benzodiazepines 12.14.3. Orexin Antagonists 12.14.4. Melatonin Receptor Antagonists 12.14.5. Other Prescription Sleep Aids 12.15. U.K. Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.15.1.1. Antihistamines 12.15.1.2. Melatonin 12.15.1.3. Valerian Roots 12.15.1.4. Other Herbal & Dietary Supplements 12.16. U.K. Insomnia Market Forecast, Non-pharmacological Treatment 12.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.16.2. Hypnotherapy 12.16.3. Other Alternative Therapies 12.17. U.K. Insomnia Market Forecast, by Prescription Sleep Aids 12.17.1. Non-benzodiazepines 12.17.2. Benzodiazepines 12.17.3. Orexin Antagonists 12.17.4. Melatonin Receptor Antagonists 12.17.5. Other Prescription Sleep Aids 12.18. France Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.18.1.1. Antihistamines 12.18.1.2. Melatonin 12.18.1.3. Valerian Roots 12.18.1.4. Other Herbal & Dietary Supplements 12.19. France Insomnia Market Forecast, Non-pharmacological Treatment 12.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.19.2. Hypnotherapy 12.19.3. Other Alternative Therapies 12.20. France Insomnia Market Forecast, by Prescription Sleep Aids 12.20.1. Non-benzodiazepines 12.20.2. Benzodiazepines 12.20.3. Orexin Antagonists 12.20.4. Melatonin Receptor Antagonists 12.20.5. Other Prescription Sleep Aids 12.21. Italy Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.21.1.1. Antihistamines 12.21.1.2. Melatonin 12.21.1.3. Valerian Roots 12.21.1.4. Other Herbal & Dietary Supplements 12.22. Italy Insomnia Market Forecast, Non-pharmacological Treatment 12.22.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.22.2. Hypnotherapy 12.22.3. Other Alternative Therapies 12.23. Italy Insomnia Market Forecast, by Prescription Sleep Aids 12.23.1. Dental clinics 12.23.2. Hospital Non-benzodiazepines 12.23.3. Benzodiazepines 12.23.4. Orexin Antagonists 12.23.5. Melatonin Receptor Antagonists 12.23.6. Other Prescription Sleep Aids 12.24. Spain Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.24.1.1. Antihistamines 12.24.1.2. Melatonin 12.24.1.3. Valerian Roots 12.24.1.4. Other Herbal & Dietary Supplements 12.25. Spain Insomnia Market Forecast, Non-pharmacological Treatment 12.25.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.25.2. Hypnotherapy 12.25.3. Other Alternative Therapies 12.26. Spain Insomnia Market Forecast, by Prescription Sleep Aids 12.26.1. Non-benzodiazepines 12.26.2. Benzodiazepines 12.26.3. Orexin Antagonists 12.26.4. Melatonin Receptor Antagonists 12.26.5. Other Prescription Sleep Aids 12.27. Rest of Europe Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.27.1.1. Antihistamines 12.27.1.2. Melatonin 12.27.1.3. Valerian Roots 12.27.1.4. Other Herbal & Dietary Supplements 12.28. Rest of Europe Insomnia Market Forecast, Non-pharmacological Treatment 12.28.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.28.2. Hypnotherapy 12.28.3. Other Alternative Therapies 12.29. Rest Of Europe Insomnia Market Forecast, by Prescription Sleep Aids 12.29.1. Non-benzodiazepines 12.29.2. Benzodiazepines 12.29.3. Orexin Antagonists 12.29.4. Melatonin Receptor Antagonists 12.29.5. Other Prescription Sleep Aids 12.30. Europe Insomnia Market Attractiveness Analysis 12.30.1. By Over-the-Counter Sleep Aids 12.30.2. Non-pharmacological Treatment 12.30.3. By Prescription Sleep Aids 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Insomnia Market Analysis 13.1. Key Findings 13.2. Asia Pacific Insomnia Market Overview 13.3. Asia Pacific Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 13.4. Asia Pacific Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.4.1.1. Antihistamines 13.4.1.2. Melatonin 13.4.1.3. Valerian Roots 13.4.1.4. Other Herbal & Dietary Supplements 13.5. Asia Pacific Insomnia Market Value Share Analysis, Non-pharmacological Treatment 13.6. Asia Pacific Insomnia Market Forecast, Non-pharmacological Treatment 13.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.6.2. Hypnotherapy 13.6.3. Others2 13.7. Asia Pacific Insomnia Market Value Share Analysis, by Prescription Sleep Aids 13.8. Asia Pacific Insomnia Market Forecast, by Prescription Sleep Aids 13.8.1. Non-benzodiazepines 13.8.2. Benzodiazepines 13.8.3. Orexin Antagonists 13.8.4. Melatonin Receptor Antagonists 13.8.5. Other Prescription Sleep Aids 13.9. Asia Pacific Insomnia Market Value Share Analysis, by Country 13.10. Asia Pacific Insomnia Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Insomnia Market Analysis, by Country 13.12. China Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.12.1.1. Antihistamines 13.12.1.2. Melatonin 13.12.1.3. Valerian Roots 13.12.1.4. Other Herbal & Dietary Supplements 13.13. China Insomnia Market Forecast, Non-pharmacological Treatment 13.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.13.2. Hypnotherapy 13.13.3. Others2 13.14. China Insomnia Market Forecast, by Prescription Sleep Aids 13.14.1. Non-benzodiazepines 13.14.2. Benzodiazepines 13.14.3. Orexin Antagonists 13.14.4. Melatonin Receptor Antagonists 13.14.5. Other Prescription Sleep Aids 13.15. India Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.15.1.1. Antihistamines 13.15.1.2. Melatonin 13.15.1.3. Valerian Roots 13.15.1.4. Other Herbal & Dietary Supplements 13.16. India Insomnia Market Forecast, Non-pharmacological Treatment 13.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.16.2. Hypnotherapy 13.16.3. Other Alternative Therapies 13.17. India Insomnia Market Forecast, by Prescription Sleep Aids 13.17.1. Non-benzodiazepines 13.17.2. Benzodiazepines 13.17.3. Orexin Antagonists 13.17.4. Melatonin Receptor Antagonists 13.17.5. Other Prescription Sleep Aids 13.18. Japan Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.18.1.1. Antihistamines 13.18.1.2. Melatonin 13.18.1.3. Valerian Roots 13.18.1.4. Other Herbal & Dietary Supplements 13.19. Japan Insomnia Market Forecast, Non-pharmacological Treatment 13.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.19.2. Hypnotherapy 13.19.3. Others2 13.20. Japan Insomnia Market Forecast, by Prescription Sleep Aids 13.20.1. Non-benzodiazepines 13.20.2. Benzodiazepines 13.20.3. Orexin Antagonists 13.20.4. Melatonin Receptor Antagonists 13.20.5. Other Prescription Sleep Aids l 13.21. ASEAN Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.21.1.1. Antihistamines 13.21.1.2. Melatonin 13.21.1.3. Valerian Roots 13.21.1.4. Other Herbal & Dietary Supplements 13.22. ASEAN Insomnia Market Forecast, Non-pharmacological Treatment 13.22.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.22.2. Hypnotherapy 13.22.3. Other Alternative Therapies 13.23. ASEAN Insomnia Market Forecast, by Prescription Sleep Aids 13.23.1. Non-benzodiazepines 13.23.2. Benzodiazepines 13.23.3. Orexin Antagonists 13.23.4. Melatonin Receptor Antagonists 13.23.5. Other Prescription Sleep Aids 13.24. Rest of Asia Pacific Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.24.1.1. Antihistamines 13.24.1.2. Melatonin 13.24.1.3. Valerian Roots 13.24.1.4. Other Herbal & Dietary Supplements 13.25. Rest of Asia Pacific Insomnia Market Forecast, Non-pharmacological Treatment 13.25.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.25.2. Hypnotherapy 13.25.3. Other Alternative Therapies 13.26. Rest of Asia Pacific Insomnia Market Forecast, by Prescription Sleep Aids 13.26.1. Non-benzodiazepines 13.26.2. Benzodiazepines 13.26.3. Orexin Antagonists 13.26.4. Melatonin Receptor Antagonists 13.26.5. Other Prescription Sleep Aids 13.27. Asia Pacific Insomnia Market Attractiveness Analysis 13.27.1. By Over-the-Counter Sleep Aids 13.27.2. Non-pharmacological Treatment 13.27.3. By Prescription Sleep Aids 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Insomnia Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Insomnia Market Overview 14.3. Middle East & Africa Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 14.4. Middle East & Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.4.1.1. Antihistamines 14.4.1.2. Melatonin 14.4.1.3. Valerian Roots 14.4.1.4. Other Herbal & Dietary Supplements 14.5. Middle East & Africa Insomnia Market Value Share Analysis, Non-pharmacological Treatment 14.6. Middle East & Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.6.2. Hypnotherapy 14.6.3. Others2 14.7. Middle East & Africa Insomnia Market Value Share Analysis, by Prescription Sleep Aids 14.8. Middle East & Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.8.1. Non-benzodiazepines 14.8.2. Benzodiazepines 14.8.3. Orexin Antagonists 14.8.4. Melatonin Receptor Antagonists 14.8.5. Other Prescription Sleep Aids 14.9. Middle East & Africa Insomnia Market Value Share Analysis, by Country 14.10. Middle East & Africa Insomnia Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Insomnia Market Analysis, by Country 14.12. GCC Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.12.1.1. Antihistamines 14.12.1.2. Melatonin 14.12.1.3. Valerian Roots 14.12.1.4. Other Herbal & Dietary Supplements 14.13. GCC Insomnia Market Forecast, Non-pharmacological Treatment 14.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.13.2. Hypnotherapy 14.13.3. Other Alternative Therapies 14.14. GCC Insomnia Market Forecast, by Prescription Sleep Aids 14.14.1. Non-benzodiazepines 14.14.2. Benzodiazepines 14.14.3. Orexin Antagonists 14.14.4. Melatonin Receptor Antagonists 14.14.5. Other Prescription Sleep Aids 14.15. South Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.15.1.1. Antihistamines 14.15.1.2. Melatonin 14.15.1.3. Valerian Roots 14.15.1.4. Other Herbal & Dietary Supplements 14.16. South Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.16.2. Hypnotherapy 14.16.3. Other Alternative Therapies 14.17. South Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.17.1. Non-benzodiazepines 14.17.2. Benzodiazepines 14.17.3. Orexin Antagonists 14.17.4. Melatonin Receptor Antagonists 14.17.5. Other Prescription Sleep Aids 14.18. Rest of Middle East & Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.18.1.1. Antihistamines 14.18.1.2. Melatonin 14.18.1.3. Valerian Roots 14.18.1.4. Other Herbal & Dietary Supplements 14.19. Rest of Middle East & Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.19.2. Hypnotherapy 14.19.3. Others2 14.20. Rest of Middle East & Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.20.1. Non-benzodiazepines 14.20.2. Benzodiazepines 14.20.3. Orexin Antagonists 14.20.4. Melatonin Receptor Antagonists 14.20.5. Other Prescription Sleep Aids 14.21. Middle East & Africa Insomnia Market Attractiveness Analysis 14.21.1. By Over-the-Counter Sleep Aids 14.21.2. Non-pharmacological Treatment 14.21.3. By Prescription Sleep Aids 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Insomnia Market Analysis 15.1. Key Findings 15.2. South America Insomnia Market Overview 15.3. South America Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 15.4. South America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.4.1.1. Antihistamines 15.4.1.2. Melatonin 15.4.1.3. Valerian Roots 15.4.1.4. Other Herbal & Dietary Supplements 15.5. South America Insomnia Market Value Share Analysis, Non-pharmacological Treatment 15.6. South America Insomnia Market Forecast, Non-pharmacological Treatment 15.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.6.2. Hypnotherapy 15.6.3. Other Alternative Therapies 15.7. South America Insomnia Market Value Share Analysis, by Prescription Sleep Aids 15.8. South America Insomnia Market Forecast, by Prescription Sleep Aids 15.8.1. Non-benzodiazepines 15.8.2. Benzodiazepines 15.8.3. Orexin Antagonists 15.8.4. Melatonin Receptor Antagonists 15.8.5. Other Prescription Sleep Aids 15.9. South America Insomnia Market Value Share Analysis, by Country 15.10. South America Insomnia Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Insomnia Market Analysis, by Country 15.12. Brazil Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.12.1.1. Antihistamines 15.12.1.2. Melatonin 15.12.1.3. Valerian Roots 15.12.1.4. Other Herbal & Dietary Supplements 15.13. Brazil Insomnia Market Forecast, Non-pharmacological Treatment 15.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.13.2. Hypnotherapy 15.13.3. Other Alternative Therapies 15.14. Brazil Insomnia Market Forecast, by Prescription Sleep Aids 15.14.1. Non-benzodiazepines 15.14.2. Benzodiazepines 15.14.3. Orexin Antagonists 15.14.4. Melatonin Receptor Antagonists 15.14.5. Other Prescription Sleep Aids 15.15. Mexico Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.15.1.1. Antihistamines 15.15.1.2. Melatonin 15.15.1.3. Valerian Roots 15.15.1.4. Other Herbal & Dietary Supplements 15.16. Mexico Insomnia Market Forecast, Non-pharmacological Treatment 15.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.16.2. Hypnotherapy 15.16.3. Other Alternative Therapies 15.17. Mexico Insomnia Market Forecast, by Prescription Sleep Aids 15.17.1. Non-benzodiazepines 15.17.2. Benzodiazepines 15.17.3. Orexin Antagonists 15.17.4. Melatonin Receptor Antagonists 15.17.5. Other Prescription Sleep Aids 15.18. Rest of South America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.18.1.1. Antihistamines 15.18.1.2. Melatonin 15.18.1.3. Valerian Roots 15.18.1.4. Other Herbal & Dietary Supplements 15.19. Rest of South America Insomnia Market Forecast, Non-pharmacological Treatment 15.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.19.2. Hypnotherapy 15.19.3. Other Alternative Therapies 15.20. Rest of South America Insomnia Market Forecast, by Prescription Sleep Aids 15.20.1. Non-benzodiazepines 15.20.2. Benzodiazepines 15.20.3. Orexin Antagonists 15.20.4. Melatonin Receptor Antagonists 15.20.5. Other Prescription Sleep Aids 15.21. South America Insomnia Market Attractiveness Analysis 15.21.1. By Over-the-Counter Sleep Aids 15.21.2. Non-pharmacological Treatment 15.21.3. By Prescription Sleep Aids 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Biocodex S A 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Astellas 16.3.3. Biocodex S A 16.3.4. Consumer Healthcare Inc. 16.3.5. Dainippon Sumitomo 16.3.6. ECR Pharmaceuticals 16.3.7. Eisai Co. 16.3.8. Flynn Pharma 16.3.9. Johnson and Johnson 16.3.10. Meda Consumer Healthcare Inc. 16.3.11. Merck and Co. Inc. 16.3.12. Neurim 16.3.13. Pernix Therapeutics 16.3.14. Pfizer Inc 16.3.15. Purdue Pharma L.P. 16.3.16. Sanofi Pasteur 16.3.17. SkyePharma 16.3.18. Takeda Pharmaceutical Company 17. Primary Key Insights

About This Report

Report ID37228
Category Healthcare
Published DateNov 2019
No of Pages179
Contact Us
Call Now